Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE
Beverly MK Biller, MD, FACP
Mark Gurnell, MD
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026 Seoul
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD
Javier Cortes, MD, PhD
What’s Next for TROP2-Directed ADCs in TNBC?
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD
Lakshi Aldredge, MSN, ANP-BC
Najat M. Watch, PA
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
The Power of Timing: Therapies That Change Outcomes
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
Jose Rubio, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
From Data to Decision: Patient Selection and Real-World Application
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
De Novo mHSPC: Recognizing the Patients Who Need More
Targeting PTEN: Why It Matters
Molecular Profiling in mHSPC: Informing Treatment Selection
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.